Success Metrics

Clinical Success Rate
96.9%

Based on 126 completed trials

Completion Rate
97%(126/130)
Active Trials
3(2%)
Results Posted
54%(68 trials)
Terminated
4(2%)

Phase Distribution

Ph phase_1
5
3%
Ph early_phase_1
1
1%
Ph phase_3
31
18%
Ph phase_2
13
8%
Ph not_applicable
33
19%
Ph phase_4
79
46%

Phase Distribution

6

Early Stage

13

Mid Stage

110

Late Stage

Phase Distribution162 total trials
Early Phase 1First-in-human
1(0.6%)
Phase 1Safety & dosage
5(3.1%)
Phase 2Efficacy & side effects
13(8.0%)
Phase 3Large-scale testing
31(19.1%)
Phase 4Post-market surveillance
79(48.8%)
N/ANon-phased studies
33(20.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

92.0%

126 of 137 finished

Non-Completion Rate

8.0%

11 ended early

Currently Active

3

trials recruiting

Total Trials

173

all time

Status Distribution
Active(10)
Completed(126)
Terminated(11)
Other(26)

Detailed Status

Completed126
unknown26
Withdrawn7
Not yet recruiting6
Terminated4
Recruiting3

Development Timeline

Analytics

Development Status

Total Trials
173
Active
3
Success Rate
96.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (0.6%)
Phase 15 (3.1%)
Phase 213 (8.0%)
Phase 331 (19.1%)
Phase 479 (48.8%)
N/A33 (20.4%)

Trials by Status

not_yet_recruiting63%
withdrawn74%
unknown2615%
terminated42%
completed12673%
enrolling_by_invitation11%
recruiting32%

Recent Activity

Clinical Trials (173)

Showing 20 of 173 trialsScroll for more
NCT05887375Phase 4

Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery

Completed
NCT05801679Phase 3

Evaluating Outcomes in Cardiac Surgery Patients Who Receive Sugammadex vs. Placebo

Completed
NCT07534475Not Applicable

Venous Tourniquet vs. Arterial Tourniquet for Seizure Monitoring in ECT

Not Yet Recruiting
NCT05328778Phase 4

Pharmacokinetics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade in Patients During Laparoscopic Surgery

Completed
NCT05788718

An Observational Study to Analyze the Prescription Pattern of Sugammadex and Its Effectiveness and Safety

Completed
NCT07309393Not Applicable

Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function

Recruiting
NCT07477132Phase 4

A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 and 24 Months Old

Not Yet Recruiting
NCT07203287Phase 4

Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease

Recruiting
NCT06634355Not Applicable

Placental Transfer of Sugammadex in the Human Placental Perfusion Model

Enrolling By Invitation
NCT07271875Phase 3

Neuromuscular Blocking Agents on Gastrointestinal Function Following Colorectal Surgery

Not Yet Recruiting
NCT05985343Phase 4

The Impact of Sugammadex on Ileus After Abdominal Wall Reconstruction

Completed
NCT05256901Phase 4

Sugammadex vs Neostigmine Reversal in Pediatric Appendectomy

Terminated
NCT05661409Phase 4

Sugammadex as Rescue Therapy

Completed
NCT06228092Phase 4

Neostigmine/Glyco-pyrrolate 50 Mikrogram/kg or Sugammadex 2 mg/kg for Reversal of Neuromuscular Blockade in Elderly Patients

Completed
NCT06225466Phase 4

Muscle Relaxation for Pediatric Adenotonsillectomy

Completed
NCT03111121Phase 4

Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy

Completed
NCT05276804Phase 3

The POUR (Postoperative Urinary Retention) Study

Completed
NCT03923556Phase 4

Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery

Completed
NCT06982092Phase 1

Using Diaphragm Ultrasonography, Sugammadex Recovers Diaphragmatic Function More Effectively Than Neostigmine.

Completed
NCT03116997Phase 3

Study of Recovery of Strength After Surgery Comparing Two Different Medications for Reversal of Muscle Relaxant

Completed

Drug Details

Intervention Type
DRUG
Total Trials
173